Eisai To Use Genomics’ Tools For Drug Discovery

The collaboration between Eisai and Genomics will focus on using genomic analyses to improve the drug development pipeline.

AsianScientist (Apr. 14, 2015) – Eisai Co., Ltd. and UK-based Genomics plc have entered into a collaborative agreement to use Genomics’ sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai’s drug discovery process, including target selection, target validation, indication selection and repositioning.

Both companies believe that human genetics and genomics can add great value to the drug development process. Genomics, the Oxford based genome analytics company, will be partnering with Eisai’s new Integrated Human Genomics (IHGx) Research Unit which operates directly under the supervision of Eisai Product Creation Systems’ chief clinical officer.

Professor Peter Donnelly, a director and founder of Genomics, says, “Genomics’ research work with Eisai will demonstrate the real value that powerful analyses of large genomic databases can add to drug development pipelines.”

“Genomics is excited to be working with one of the world’s leading research and development-based pharmaceutical companies in the rapidly growing area of genomic analysis. This exciting new area promises to potentially make a positive difference to medicine,” adds John Colenutt, CEO of Genomics.


Source: Eisai.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist